ArticleAdvances in therapy2022

Cost-Effectiveness of Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed or Refractory Large B Cell Lymphoma: No Impact of Site of Care.

Alice Kate Cummings Joyner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.